pathway. a, PDAC proliferation requires both glucose and Gln. Cells were plated in complete media (10 mM glucose and 2 mM Gln) which was replaced the following day with glucose-or Gln-free medium supplemented with 10% dialysed fetal bovine serum. b, Relative clonogenic growth of 8988T cells expressing a control shRNA (shGFP) or two independent shRNAs to GLS1. c, Schematic overview of GLUD1-or transaminase-mediated Glu metabolism. d, Relative clonogenic growth of 8988T cells. a-KG (4 mM), NEAA mixture (0.1 mM glycine, alanine, aspartate, asparagine, proline and serine) or the combination was added to media following Gln withdrawal. a-KG, a-ketoglutarate; Glc, glucose; Gln, glutamine; Glu, glutamate; NEAA, non-essential amino acid. Error bars represent s.d. of triplicate wells from a representative experiment. **P , 0.01. Glu can be converted into a-ketoglutarate (a-KG) to replenish the TCA cycle through two mechanisms 1 ; either by glutamate dehydrogenase (GLUD1) or transaminases ( Fig. 1c ). Indeed, many cancer cells rely on GLUD1-mediated Glu deamination to fuel the TCA cycle 7 , and a-KG has been shown to be an essential metabolite in Gln metabolism 8 . Surprisingly, dimethyl a-KG 9 did not restore growth upon Gln deprivation ( Fig. 1d ), whereas the combination of a-KG and an NEAA mixture (the output of transaminase-mediated Glu metabolism) markedly rescued proliferation in multiple PDAC lines ( Fig. 1d and Supplementary Fig. 2d, e ). Together, these data indicate that PDAC cells metabolize Gln in a manner that is different from canonical models 10 and that transaminases may be critical for Gln metabolism in PDAC.
To confirm the importance of transaminases in PDAC Gln metabolism, we treated PDAC cells with either aminooxyacetate (AOA), a paninhibitor of transaminases 11 , or epigallocatechin gallate (EGCG), an inhibitor of GLUD1 12 . Whereas EGCG had no effect on PDAC growth, AOA treatment robustly inhibited the growth of multiple PDAC cell lines ( Supplementary Fig. 3 ). Consistent with these results, GLUD1 knockdown also had no effect on PDAC growth ( Fig. 2a ). To identify the specific transaminase(s) involved in PDAC Gln metabolism, we inhibited a panel of Glu-dependent transaminases (aspartate, alanine and phosphoserine transaminase) individually using RNAi and examined the effect on PDAC growth. Among this panel, knockdown of the aspartate transaminase GOT1 significantly impaired PDAC growth in multiple PDAC cell lines and primary PDAC cells ( Fig. 2a and Supplementary Fig. 4 , 5).
We next explored the direct effects of GOT1 on Gln metabolism by performing targeted metabolomic analysis in GOT1 knockdown PDAC cells using uniformly 13 C-labelled Gln ([U-13 C 5 ]Gln) as a tracer 4, 13 . GOT1 catalyses the conversion of aspartate (Asp) and a-KG into oxaloacetate (OAA) and Glu in the cytoplasm. Indeed, GOT1 knockdown led to increased Gln-derived Asp (and total Asp) and decreased OAA ( Fig. 2b and Supplementary Fig. 6a ). Interestingly, we also observed a significant decrease in the ratio of reduced-to-oxidized glutathione (GSH:GSSG; Fig. 2b and Supplementary Fig. 6b ), suggesting that GOT1 may play a role in the maintenance of cellular redox homeostasis. It should be noted that the changes in metabolite abundance described in this experiment are representative of the total cellular metabolite pool 
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due to technical limitations associated with organelle-specific metabolite isolation. Importantly however, the results we obtained are consistent with what one would expect if flux through GOT1 was impaired.
In PDAC, we recently demonstrated that oncogenic KRAS enhances the flux of glycolytic intermediates specifically through the nonoxidative arm of the pentose phosphate pathway (PPP) to support DNA/RNA biosynthesis without affecting the NADPH-producing oxidative arm 4 . This decoupling of ribose biogenesis from NADPH production by KRAS suggests that PDAC cells may rely on an alternative mechanism to maintain cellular redox balance. Indeed, inhibition of the oxidative PPP in PDAC by knockdown of the rate-limiting enzyme glucose-6-phosphate dehydrogenase (G6PD) had minimal effect on reactive oxygen species (ROS) levels and, consistent with this, glucose deprivation had only a modest impact on ROS ( Supplementary  Fig. 6c ). Therefore, we speculated that the GOT1-mediated conversion of Gln-derived Asp into OAA functions in a pathway that is used to generate the NADPH which could be used to maintain redox balance. To test this hypothesis, we assessed ROS levels upon Gln deprivation in the absence or presence of OAA. Indeed, Gln deprivation induced ROS, and OAA could partially rescue the elevated ROS levels (Fig. 2c ). GOT1 knockdown also increased ROS levels, which again were significantly restored upon supplementation with OAA ( Fig. 2d) .
Given that Gln-derived malate (and total malate) was significantly reduced upon GOT1 knockdown ( Fig. 2b ), we suspected that Glnderived OAA is metabolized into malate, which is used by malic enzyme (ME1) to create NADPH, providing the reducing power to maintain reduced glutathione pools 14 . Indeed, malate was able to partially rescue the oxidative stress imposed by Gln-deprivation ( Fig. 2e ) or GOT1 knockdown (Fig. 2f ). These data are consistent with a model whereby Gln-derived Asp is converted by GOT1 into OAA, then converted into malate by malate dehydrogenase (MDH1) and subsequently oxidized by ME1 into pyruvate and reducing power in the form of NADPH (Fig. 2g ). Consistent with this pathway, metabolomic analysis of [U-13 C 5 ]Gln tracing in ME1 knockdown cells revealed a significant increase in Asp, malate and OAA and decreased GSH ( Fig. 2h and Supplementary Fig. 6d ). Furthermore, knockdown of GOT1 and ME1 markedly increased the cellular NADP 1 /NADPH ratio ( Fig. 2i ), whereas inhibition of other cytosolic sources of NADPH (G6PD or isocitrate dehydrogenase, IDH1) had no effect on NADP 1 /NADPH ratios or ROS ( Fig. 2i and Supplementary Fig. 6c ). Together, the data suggest that PDAC use Gln through the pathway depicted in Fig. 2g to increase the NADPH/NADP 1 ratio for maintenance of redox homeostasis. Lastly, Gln tracing kinetic flux experiments in GOT1 knockdown cells clearly demonstrate decreased flux through this pathway ( Fig. 2j and Supplementary Fig. 7 ). Interestingly, lactate in the 13 C-tracing experiments was minimally labelled, indicating that the pyruvate produced by ME1 is not used to make lactate by lactate dehydrogenase and has a yet undetermined fate.
The majority of Asp in PDAC cells (50-75%) is derived from Gln, as evidenced by 13 C-labelling ( Supplementary Fig. 6a, d and 8a) . In principle, uniformly 13 C-labelled Asp can be derived from Gln following either (1) the GLUD1-mediated conversion of Glu to a-KG (and its subsequent traversing through the TCA cycle) or (2) the mitochondrial aspartate transaminase (GOT2)-mediated conversion of Glu and OAA to a-KG and Asp. Of these two enzymes, only GOT2 knockdown significantly affected PDAC growth ( Fig. 2a and Supplementary Fig.  8b ). Consistent with this observation, GLUD1 knockdown did not affect Asp biosynthesis from Gln, whereas GOT2 knockdown resulted in a significant decrease in Gln-derived Asp in PDAC cells (Supplementary Fig. 8a, c) .
We next tested whether other components of this pathway are also necessary to support PDAC growth. Indeed, knockdown of either MDH1 or ME1 markedly inhibited clonogenic survival of PDAC cells (Fig. 3a, b and Supplementary Fig. 9 ) in a manner similar to GOT1 knockdown. As a further test of enzyme knockdown specificity, we investigated the ability of central metabolites in this pathway to rescue PDAC growth upon Gln deprivation. First, we confirmed that exogenously added metabolites permeated the cell and populated metabolite pools ( Supplementary Fig. 10 ). Next, we demonstrated that the combination of GOT1 substrates, Asp and a-KG, could rescue cell growth in Gln-free conditions ( Supplementary Fig. 11a ). Additionally, OAA permitted PDAC growth under Gln-free conditions in multiple PDAC cell lines ( Fig. 3c and Supplementary Fig. 11 ) as well as upon both GLS (Supplementary Fig. 12 ) and GOT1 knockdown ( Fig. 3d and Supplementary  Fig. 13a, b) . Lastly, the addition of dimethyl-malate 15 was able to partially rescue PDAC cell growth upon Gln deprivation ( Supplementary  Fig. 13c ) or GOT1 knockdown ( Supplementary Fig. 13d ).
Next, to confirm that the OAA or malate rescue of PDAC growth upon Gln deprivation was through maintenance of redox homeostasis, we treated cells grown in Gln-free conditions with a cell-permeable GSH analogue. Remarkably, GSH dramatically rescued clonogenic growth following Gln-deprivation ( Fig. 3e and Supplementary Fig. 11c ) or GOT1 knockdown ( Fig. 3d and Supplementary Fig. 13a, b) . GSH was also able to rescue either MDH1 or ME1 knockdown ( Supplementary  Fig. 14a ). Near-identical results were also seen with the antioxidant N-acetylcysteine (NAC) (Fig. 3e, f and Supplementary Fig. 14b, c) . Together, these data support the idea that Gln is used by PDAC cells to maintain redox homeostasis, which is required to support cellular proliferation.
As further confirmation of the importance of this pathway in PDAC, we suppressed GOT1, MDH1 and ME1 expression using two lentiviral short hairpin RNAs (shRNAs) in PDAC cells and assessed their ability to grow as xenografts. Consistent with our in vitro results, both GLUD1 shRNAs had no effect on tumour growth ( Supplementary Fig. 15 ). In contrast, GOT1, MDH1 and ME1 knockdown each robustly diminished tumour growth (Fig. 3g) . These data provide further support for the critical role of this pathway in Gln metabolism and PDAC tumour growth. and ME1 supports PDAC growth by maintaining redox balance. a, b, Relative clonogenic growth of 8988T cells expressing a control shRNA (shGFP) or two independent shRNAs to MDH1 or ME1. c, e, Relative clonogenic growth of 8988T cells under conditions indicated. Cells were plated in complete culture media (10 mM glucose and 2 mM Gln), which was replaced the following day with Gln-free medium supplemented with OAA (4 mM), GSH (4 mM) or N-acetylcysteine (NAC) (4 mM). d, f, Relative clonogenic growth of 8988T cells expressing a control shRNA (shGFP) or two independent shRNAs to GOT1 with or without OAA (4 mM), GSH (4 mM) or NAC (4 mM). Error bars represent the s.d. of triplicate wells from a representative experiment (a-f). g, Xenograft growth of 8988T cells expressing a control shRNA (shGFP), shRNAs to GOT1 (1 and 2), MDH1 (1 and 2) or ME1 (1 and 2) in mice. Error bars represent s.e.m. (n 5 10). *P , 0.05; **P , 0.01.
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In contrast to PDAC, this pathway seems to be dispensable in normal cells. Indeed, treatment of non-transformed human pancreatic ductal cells (HPDEs) and human diploid fibroblasts (IMR90) with AOA had only modest effects on growth ( Supplementary Fig. 16a ). HPDE cells, unlike PDAC cells, were significantly sensitive to EGCG, suggesting a greater reliance on the activity of GLUD1 ( Supplementary  Fig. 16b ). Consistent with these results, GOT1 knockdown did not impair the growth of HPDE and IMR90 ( Supplementary Fig. 16c ). We also obtained similar results in mouse ductal epithelial cells (mPDE) and mouse PDAC cell lines, with the mPDEs being highly insensitive to AOA and GOT1 knockdown and two independently derived mouse PDAC lines showing significant sensitivity to AOA and GOT1 knockdown ( Supplementary Fig. 16d, e ). Furthermore, using an inducible shGOT1 construct, we demonstrated that mouse PDAC rely on GOT1 to sustain tumour growth in vivo ( Supplementary   Fig. 17 ). Collectively, these data demonstrate that the GOT1-mediated usage of the Gln carbon skeleton is a metabolic adaptation that PDAC, and not normal cells, have uniquely acquired to support growth.
Our previous work demonstrated that anabolic glucose metabolism in PDAC is controlled by oncogenic KRAS, which leads to altered expression of a number of rate-limiting metabolic enzymes 4 . To investigate the role of KRAS in the reprogramming of Gln metabolism, we assessed the expression of GOT1 and GLUD1 upon knockdown of KRAS in PDAC cells. Interestingly, KRAS knockdown resulted in a marked increase in GLUD1 and a decrease in GOT1 expression at the transcriptional level (Fig. 4a) , as well as the protein level (Fig. 4b ) in multiple PDAC lines ( Supplementary Fig. 18a ). Additionally, using five independent orthotopic tumours derived from our inducible KRAS PDAC model 4 , we show that expression of GOT1 increased and GLUD1 decreased in an oncogenic KRAS-dependent manner in vivo ( Supplementary Fig. 18b ). These findings demonstrate that, in PDAC, oncogenic KRAS plays a critical role in coordinating the shift in Gln metabolism to maintain tumour growth and survival.
We next assessed the sensitivity of PDAC cells to either AOA or EGCG upon KRAS knockdown using 8988T cells, a cell line that is not dependent on KRAS for survival 16 . Consistent with our previous results, AOA significantly inhibited clonogenic growth, whereas EGCG had minimal effects. Interestingly, KRAS knockdown made the cells significantly more resistant to AOA and sensitive to EGCG ( Fig. 4c and Supplementary Fig. 18c ). To confirm the role of oncogenic KRAS in the reprogramming of Gln metabolism, a targeted metabolomic analysis using [U- 13 C 5 ]Gln was performed upon KRAS knockdown. Indeed, the changes observed were consistent with KRAS supporting the anabolic metabolism of Gln, where multiple metabolites in the GOT1-dependent pathway were significantly deregulated ( Fig. 4d and Supplementary Fig. 19 ).
Given the importance of Gln metabolism in maintaining the redox state of PDAC, we speculated that inhibition of anabolic Gln metabolism may sensitize PDAC to oxidative stress. To test this concept, we inhibited Gln metabolism in PDAC cells using a GLS inhibitor and examined whether this would synergize with hydrogen peroxide (H 2 O 2 ) treatment. First, we found that two chemically distinct GLS inhibitors 8, 17 had a growth-suppressive effect on both human and mouse PDAC cells ( Supplementary Fig. 20a, b) , consistent with the GLS knockdown data (Fig. 1b ). In addition, when combined with H 2 O 2 , this effect was notably augmented, indicating that PDAC cells are markedly more sensitive to ROS when Gln metabolism is impaired ( Fig. 4e and Supplementary Fig. 20c ). This finding may have significant therapeutic implications, given that clinical grade GLS inhibitors are being developed 18 and that standard PDAC therapies (such as radiation) lead to the generation of ROS. Moreover, because this aspect of Gln metabolism does not seem as critical in normal cells, these data indicate an accessible therapeutic window.
Collectively, our data reveal a novel dependence on the transaminases GOT2 and GOT1 for metabolism of the glutamine carbon skeleton in PDAC. These reactions lead to the cytosolic conversion of aspartate into OAA, malate and then pyruvate and are required to sustain PDAC growth, probably through maintaining redox balance. Importantly, our work also demonstrates that oncogenic KRAS mediates this reprogramming of glutamine metabolism (Fig. 4f ). Although this pathway is critical for redox balance and cell growth in PDAC, it does not preclude the involvement of other pathways that may contribute to redox balance such as glutathione synthesis 9, 19, 20 or an NRF2dependent mechanism 21 . Furthermore, there may be cell-type-specific differences, as KRAS-transformed fibroblasts require both GLUD1 and transaminases for cell growth 22 . Lastly, these findings may have implications for future therapeutic approaches as inhibition of glutamine metabolism in PDAC can potentially synergize with therapies that increase intracellular reactive oxygen species, such as chemotherapy and radiation. 
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METHODS SUMMARY
Proliferation and clonogenic assays were performed as previously described 23 .
To characterize Gln metabolism, targeted liquid chromatography-tandem mass spectrometry was performed 4 . Briefly, cells were grown in complete media and transferred into Gln-free media supplemented with [U-13 C 5 ]Gln overnight (steady state) or for the indicated time points (flux analyses). For subcutaneous xenografts, PDAC cells infected with lentiviral shRNAs to suppress target gene expression were suspended in 100 ml HBSS and injected subcutaneously into the lower flank of NCr nude mice. For mouse xenografts, murine PDAC cells stably infected with a doxycycline-inducible GOT1 shRNA construct were injected. Animals were fed with doxycycline water starting on the day of injection or when tumour volume reached ,50 mm 3 . Complete images of western blots are presented in Supplementary Fig. 21 .
